Intranasal Lorazepam Versus Intramuscular Paraldehyde in Paediatric Convulsions

• Status: Completed
• Trial end date: 2005-06-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to evaluate intranasal lorazepam in paediatric status epilepticus. This is a potentially, more effective, safer and cheaper treatment for a common paediatric medical emergency compared to our present first line therapy intramuscular paraldehyde.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: University of Malawi College of Medicine
• Treatments: Lorazepam; Paraldehyde

Criteria

Inclusion Criteria:

• Children aged between 2 months and 12 years

• Presenting with generalised convulsions

Exclusion Criteria:

• Any child who had received an anticonvulsant agent within 1 hour of presentation

• Seizure stopped with rapid cooling or treatment of hypoglycaemia

• Features consistent with organophosphate poisoning, hepatic or hypertensive encephalopathy